MedTrace Logo

Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women

NCT01508858 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-01-24

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide changes AUC (area under the curve) of ethinylestradiol and levonorgestrel administered as a combination contraceptive drug (Neovletta®).

Conditions

Interventions

DRUG

liraglutide

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

DRUG

placebo

Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order

DRUG

levonorgestrel / ethinylestradiol

One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01508858 on ClinicalTrials.gov